Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
P/P/P 0.02/40/2mg/mL(Prostaglandin//Papaverine/Phentolamine) Injection Recalled by Ranier's Compounding Laboratory Due to Lack of Assurance of Sterility: Practices at firm...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Ranier's Compounding Laboratory directly.
Affected Products
P/P/P 0.02/40/2mg/mL(Prostaglandin//Papaverine/Phentolamine) Injection, 0.02/40/2 mg/mL, 1 mL vial, Rx only, Ranier's Rx Laboratory, 1107 Lowry Avenue Suite A, Jeannette, PA 15644.
Quantity: 1 vial
Why Was This Recalled?
Lack of Assurance of Sterility: Practices at firm may call into question the sterility of products intended to be sterile.
Where Was This Sold?
Product was distributed within the state of Pennsylvania.
About Ranier's Compounding Laboratory
Ranier's Compounding Laboratory has 15 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report